In vivo toxicity of cationic micelles and liposomes  by Knudsen, Kristina Bram et al.
BASIC SCIENCE
Nanomedicine: Nanotechnology, Biology, and Medicine
11 (2015) 467–477Original Article
In vivo toxicity of cationic micelles and liposomes,
Kristina Bram Knudsen, PhDa,b,1, Helle Northeved, DVM, PhDa, Pramod Kumar EK, PhDc,
Anders Permin, DVM, PhDd, Torben Gjetting, PhDc, Thomas L. Andresen, PhDc,
Steen Larsen, DVM, PhDa, Karen Malene Wegener, DVM, PhDa, Jens Lykkesfeldt, PhD, DScb,
Kim Jantzen, MScb, Steffen Loft, MDb, Peter Møller, PhDb, Martin Roursgaard, PhDb,⁎
aH. Lundbeck A/S, Valby, Denmark
bFaculty of Health and Medical Science, University of Copenhagen, Denmark
cCenter for Nanomedicine and Theranostics, Technical University of Denmark, DTU Nanotech, Lyngby, Denmark
dDTU Food, Technical University of Denmark, Søborg, Denmark
Received 31 March 2014; accepted 8 August 2014
nanomedjournal.comAbstract
This study investigated toxicity of nanocarriers comprised of cationic polymer and lipid components often used in gene and drug delivery,
formulated as cationic micelles and liposomes. Rats were injected intravenously with 10, 25 or 100 mg/kg and sacrificed after 24 or 48 h, or 24 h
after the last of three intravenous injections of 100 mg/kg every other day. Histological evaluation of liver, lung and spleen, clinical chemistry
parameters, and hematology indicated little effect of treatment. DNA strand breaks were increased in the lung and spleen. Further, in the dose
response study we found unaltered expression levels of genes in the antioxidant response (HMOX1) and repair of oxidized nucleobases (OGG1),
whereas expression levels of cytokines (IL6, CXCL2 and CCL2) were elevated in lung, spleen or liver. The results indicate that assessment of
genotoxicity and gene expression add information on toxicity of nanocarriers, which is not obtained by histology and hematology.
From the Clinical Editor: This study investigates the toxicity of cationic micelles and liposomes utilized as nanocarriers in gene and drug
delivery, demonstrating its effects on the lungs, spleen and liver.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license (http://creativecommons.
org/licenses/by-nc-sa/3.0/).
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468 K.B. Knudsen et al / Nanomedicine: Nanotechnology, Biology, and Medicine 11 (2015) 467–477Liposomes show great possibilities as drug carriers and are
already used as drug delivery systems in treatment of cancer,12,13
but they are occasionally known to induce complement
activation which can lead to hypersensitivity reactions.14,15
Liposomes consist of lamellar phospholipid bilayers surrounding
aqueous compartments, where the composition can be altered, in
order to control the targeting, distribution, drug delivery and
toxicity.16,17 Another great potential for drug delivery is
polymeric micelles, which are formed by amphiphilic copoly-
mers, with a hydrophilic shell and a hydrophobic core.
The micelles can be constructed in small sizes of 15–80 nm,
and are suggested as promising carriers of poorly water soluble
drugs due to their hydrophilic shell.16,17 For gene transfection,
the use of polymers has shown to be successful in vitro; however
cellular uptake, gene transfection and cytotoxicity are dependent
on the properties of the specific polymers. These properties
include size, structure and surface charge, which all have to be
considered when constructing new polymers.18,19
Adverse effects of pharmaceuticals can be attributed to their
lack of targeting specificity. Improving this parameter by
implementing a nanocarrier could decrease the risk of unwanted
adverse effects as found by Pereverzeva et al, where an intravenous
injection of the cancer drug doxorubicin in rats showed a reduced
cardio- and testicular toxicity when being encapsulated by
polysorbate 80 coated NPs.20 However, there is a potential risk
when using nanomaterials, a consideration supported by findings
of toxicological effects of e.g. metal oxides, carbon nanotubes or
combustion particles that may promote inflammation, cytotoxicity
and genotoxicity in lungs after airway exposure21-23 and to
promote allergic sensitization.24 Due to limited information
available in terms of potential toxicity, including genotoxicity
and inflammation,25,26 of NPs for drug delivery, we conducted a
dose–response study of systemic NP administration by intrave-
nous (IV) injection to mimic the delivery route of a drug carrier. In
the present study we investigated the short term toxicity of a well-
characterized cationic polymeric micelle system and a cationic
standard DOTAP/CHOL liposome used in gene delivery.27 We
assessed the toxicological endpoints by histopathology, hematol-
ogy and clinical chemistry parameters. We further investigated
genotoxicity and gene expression of inflammatorymarkers (CCL2,
CXCL2, IL6), oxidative stress response (HMOX1) and repair of
oxidatively-generated DNA nucleobases such as 8-oxo-7,8-
dihydroguanine (8-oxoGua) and ring-opened formamidopyrimi-
dine lesions (OGG1), all of these markers have been used before in
relation to nanotoxicology.28,29 The level of DNA damage was
measured by the extensively validated comet assay that has been
adopted by OECD in a draft guideline for the testing of chemicals
(2012) and the ICH S2 guidelines, although it is not commonly
implemented in toxicological screening. The comet assay
measures the level of DNA damage directly as strand breaks
(SB) or as additionally DNA damage originating from oxidatively
damaged DNA that can result in pre-mutagenic lesions that are
measured by enzymatic treatment of the samples and described as
formamidopyrimidine DNA glycosylase (FPG) sensitive sites.30
We conducted a sighting-study in order to establish the dose
area of interest, where rats were given repeated IV injections of
NPs in order to characterize the toxicological effects of high
doses of the NPs in a seven day repeated dose study. Thefindings from this study were used to further evaluate the NPs in
a dose response study, where time and doses were evaluated after
a single administration of NPs and examined after 24 or 48 h.
The particles were tested as empty vesicles without ligands
attached and without any associated drugs, to establish the
immediate toxicity of the pristine drug carrier.Methods
Liposomes
Lipids were purchased from Avanti Polar Lipids, Alabaster,
AL, USA. Cationic liposomes were prepared from N-[1-(2,3-
dioleyl)propyl]-N,N,N-trimethylammonium-chloride (DOTAP,
synthetic) and cholesterol (plant source) at a concentration of
10 mg/ml in sterile phosphate-buffered saline (PBS) as previously
described.31 Briefly, equimolar amounts of DOTAP and
cholesterol were dissolved in chloroform and mixed in a glass
vial. The solvent was evaporated under an argon gas stream and the
lipid film was dried by high-vacuum overnight. Hydration was
performed in PBS at 50 °C for 2 h followed by sonication
for 30 min using a Bransonic water bath (MT-1510, 42 kHz,
80 W, setting “sonics”, Branson Ultrasonics, Danbury, CT, USA)
as previously described.32
For characterization of the liposomes, 20 μl of cationic
liposomes were diluted in 1.7 ml buffer (glucose (5%), Na-
HEPES (10 mM, pH 7.4) in disposable cuvettes and the size
distribution of the NPs was measured by dynamic light scattering
(DLS) using a ZetaPALS Zeta Potential Analyzer (Brookhaven
Instruments, NY, US) at standard settings, typically 10 sub-runs
of 30 seconds. Data were fitted using built-in software to
estimate size and polydispersity index (PDI). Subsequently, zeta
potential was measured in same sample using a conditioned
electrode, typically by 10 runs observing the relative residual from
model fitting,P b 0.04. The preparation had an average size of 92 ±
1 nm (average ± standard error), polydispersity index 0.14 and a
zeta potential of +53 ± 2 mV.Micelles
The amphiphilic triblock-copolymer poly(methylmethacry-
late)-b-poly(aminoehyl methacrylate)-b-poly(ethyleneglycol)
(PMMA-b-PAEMA-b-PEG) (500 mg, 0.04 mmol) synthesized
by our previously described method,33 was dissolved in 14 ml of
DMF (SigmaAldrich, Dorset, UK). To this clear polymer solution,
4 ml of MilliQ water was added during constant stirring within a
time interval of 30 min followed by drop wise addition of 24 ml
MilliQwater. The cloudymicelle solutionwas then transferred into
a dialysis tube (MWCO = 12 kDa) and dialysis was performed
against MilliQ water for two days (Dh = 50 ± 1 nm, PDI 0.10,
zeta potential of 32 ± 3 mV, measured in glucose (5%), Na-
HEPES (10 mM, pH 7.4) and then against PBS buffer (pH 7.4) for
another three days. This procedure was also described
previously.32,34 The final micelle concentration was 9.9 mg/ml.
The stability of the particle suspension was tested after
storage for 1 month without any significant change in size or
zeta potential.
Table 1
Layout of the study groups.
Single
dose study
Repeated
dose study
PBS (24 and 48 h) n = 8*
PBS (7 days)** n = 6
Micelle 10 mg/kg (24 h) n = 8
Micelle 25 mg/kg (24 h) n = 8
Micelle 100 mg/kg (24 h) n = 8
Micelle 100 mg/kg (48 h) n = 8
Micelles 100 mg/kg (seven days)** n = 6
Liposome 10 mg/kg (24 h) n = 8
Liposome 25 mg/kg (24 h) n = 8
Liposome 100 mg/kg (24 h) n = 8
Liposome 100 mg/kg (48 h) n = 8
Liposome 100 mg/kg (7 days)** n = 6
Total n 72 18
* PBS groups 24 and 48 h are pooled. **Three administrations every other
day over seven days.
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Ninety male Han Wistar rats, (Crl:WI (Han)) were obtained
from Charles River Wiga GmbH, Germany. Only male rats were
used in the present study because a pilot study did not reveal any sex
differences onweight gain, hematology and clinical chemistry (data
not shown). The rats were four weeks old at arrival andwere housed
in humidity and temperature-controlled ventilated cupboards
(Scantainers, Scanbur Technology, Karlslunde, Denmark) with
two or three rats per cage after randomization. They were
acclimatized for 1–2 weeks prior to examination and a 12 h day/
night cycle was maintained. A standard rodent diet (Altromin 1324,
Brogaarden, Denmark) and water were provided ad libitum. Food
consumption was recorded per cage on a weekly basis. Body-
weights (BW) were recorded three times (every 2nd day) in the
week before treatment and on a daily basis during the study. Cage-
side clinical observations were conducted several times daily during
the dosing period and changes were recorded.
The design of the two study parts is shown in Table 1. In the
single-dose study 72 rats were administered cationic particles
(10, 25 or 100 mg/kg BW) or PBS by IV injection (n = 8 per
group) once and sacrificed after 24 or 48 h. In the repeated dose
study 18 rats were administered cationic particles (100 mg/kg
BW) or PBS (n = 6 per group) IV on day 1, 4 and 7 and
sacrificed day 8 or 24 h after the last dose. Some toxicological
endpoints from the repeated dose study not included here
have been published previously.32 The rats were sacrificed by
exsanguination while anaesthetized by Avertin (Ampliqon,
Odense, Denmark) 10 ml/kg BW intraperitoneally and after
collection of intracardial blood for analyses. Organs (liver, lungs,
spleen, kidneys, adrenal glands, urinary bladder, jejunum, ileum,
colon, caecum, duodenum, rectum, lymph nodes (mesenteric and
mandibular), thymus and brain) were isolated and examined
macroscopically. The weights of brain, liver, spleen, kidneys,
adrenal glands, lungs and thymus were recorded and individual
organ to BW ratios were calculated. All gross lesionswere retained
and examined. Tissue samples frombrain, kidneys, liver, lungs and
spleen were snap frozen in liquid nitrogen for genotoxicity tests.All experiments were conducted under the Danish Federal
guidelines for use and care of laboratory animals and were
approved by the Danish Animal Inspectorate.
Sample collection for hematology and clinical chemistry
Intracardial blood samples were drawn for hematology
(suspended in 1.6 mg EDTA/ml; Sarstedt, Nümbrecht, Germany)
including red- and white blood cell count, hemoglobin, hematocrit
and platelet count, by an Advia 120 (Siemens Healthcare
Diagnostics, Tarrytown, NY, USA). Further, blood was used for
clinical chemistry (suspended in 35 international units Heparin/ml;
Sarstedt, Nümbrecht, Germany) with centrifugation at 2200×g for
15 min at 6 °C for separation of plasma stored at −20 °C until
analysis. Clinical chemistry parameters, alanine amino transferase,
alkaline phosphatase, aspartate transaminase, albumin, cholesterol,
creatinin, glucose, urea, calcium, chloride, potassium, sodium,
phosphate and bilirubin, were analyzed on a Pentra 400 (Horiba
ABX, Montpellier, France).
Histology
Tissue samples from the collected organs and gross lesions
were fixed in 4% neutral buffered formaldehyde solution
for at least 48 h. Samples from liver, lung, spleen, kidney,
brain and gross lesions were trimmed, dehydrated on a Leica
ASP300S (Leica Microsystems, Wetzlar, Germany) and embedded
in paraffin. Sections were cut at 5 μm on a Shandon Finesse
Microtome (Axlab, Vedbæk, Denmark). Sections for light micro-
scopic examinations were stained with Haematoxylin and Eosin
(H&E-staining) in a Leica ST4040 Linear Staining System (Leica
Microsystems, Wetzlar, Germany). The sections were examined by
light microscopy (Leica Microsystems, Wetzlar, Germany).
Genotoxicity
Tissues were homogenized into 1.5 ml ice-cold Merchants
buffer followed by filtration through a 80 μm pore filter
(Millipore) as described previously.32,35 The filtrate was
resuspended in 37 °C agarose and transferred to a Gelbond®
Film (Lonza, Basel, Switzerland). Cells were lysed overnight and
subsequently incubated with FPG (45 min, 37 °C) or buffer.
After the enzyme treatment, the samples were submerged in
alkaline electrophoresis buffer at pH 13 for 40 min before they
were electrophoresed in the same solution (25 V, 200 mA,
20 min, 4 °C). Afterwards, they were washed in neutral buffer
(0.4 M Trizma base, pH 7.5, 15 min, 25 °C) and finally fixed
with 96% ethanol (2 h, 25 °C). The DNA was stained with
YOYO-1 (Life Technologies, Nærum, Denmark) and damage
was scored in a fluorescence microscope (Olympus CX40) by
visual classification according to a 5-class scoring system and
transformed to lesions/106 base pairs by a calibration curve as
described previously.30 The samples were scored in duplicate
and repeated on three different days, and the level expressed as
mean lesions/106 basepairs. The results are expressed as SB and
FPG sensitive sites (FPGss). The latter represents the net level of
lesions that have been detected by the FPG enzyme (difference
in DNA damage between samples that have been treated with
FPG enzyme or buffer). The FPGss represent oxidatively-
Table 2
Clinical chemistry and hematology from single dose study for all groups reported as mean ± SD (n = 8) for animals exposed to control (PBS) or micelles.
Parameters Micelle Groups ± SD
Control 10 mg/kg 25 mg/kg 100 mg/kg 100 mg/kg (48 h)
Body weight (g) 141 ± 18.9 125 ± 20.7 133 ± 25.4 134 ± 18.1 147 ± 14.9
Erythrocytes (1012/L) 5.72 ± 5.31 5.9 ± 4.30 5.92 ± 5.17 5.87 ± 2.61 6.18 ± 4.8
Hemoglobin (mmol/L) 7.00 ± 0.42 7.08 ± 0.59 6.90 ± 0.57 6.96 ± 0.39 7.16 ± 0.42
Hematocrit (L/L) 0.35 ± 0.03 0.36 ± 0.03 0.36 ± 0.03 0.36 ± 0.02 0.37 ± 0.03
Thrombocytes (1011/L) 9.12 ± 5.73 8.80 ± 1.01 8.62 ± 1.35 9.26 ± 8.56 9.04 ± 1.36
Leucocytes (109/L) 4.25 ± 1.07 3.92 ± 1.22 3.55 ± 1.19 4.11 ± 1.07 4.45 ± 1.44
Reticulocytes (1011/L) 4.71 ± 6.81 4.66 ± 6.42 4.45 ± 6.41 4.60 ± 9.03 4.23 ± 4.26
Chloride (mmol/L) 99.9 ± 1.25 100 ± 1.49 101 ± 1.41 101 ± 0.74 100 ± 0.99
Potassium (mmol/L) 4.41 ± 0.28 4.24 ± 0.47 4.09 ± 0.44 4.28 ± 0.36 4.53 ± 0.58
Sodium (mmol/L) 133 ± 1.73 133 ± 1.46 133 ± 2.27 134 ± 1.85 134 ± 1.77
Bilirubin (μmol/L) 1.04 ± 0.54 0.96 ± 0.25 1.15 ± 0.34 0.88 ± 0.47 0.81 ± 0.44
Alkaline Phosphatase (μkat/L) 4.90 ± 0.81 5.63 ± 1.13 5.03 ± 1.14 4.83 ± 0.69 4.39 ± 1.16
Phosphorus (mmol/L) 2.31 ± 0.55 2.11 ± 0.30 2.01 ± 0.48 2.38 ± 0.46 2.36 ± 0.27
Albumin (g/L) 26.7 ± 0.70 27.06 ± 1.46 27.2 ± 1.44 28.0 ± 1.12* 28.1 ± 1.38*
Triglycerides (mmol/L) 1.24 ± 0.33 1.10 ± 0.20 1.06 ± 0.41 1.12 ± 0.58 1.30 ± 0.42
Aspartat aminotransferase (μkat/L) 1.59 ± 0.28 1.61 ± 0.36 1.55 ± 0.20 1.50 ± 0.19 1.48 ± 0.35
Urea (mmol/L) 7.43 ± 1.20 5.96 ± 0.56* 6.30 ± 0.97* 6.36 ± 1.17* 7.51 ± 0.77
Calcium (mmol/L) 3.26 ± 0.22 3.11 ± 0.12 3.03 ± 0.06* 3.16 ± 0.12 3.30 ± 0.30
Alanin aminotransferase (μkat/L) 0.88 ± 0.12 0.88 ± 0.15 0.87 ± 0.08 0.92 ± 0.10 0.86 ± 0.12
Cholesterol (mmol/L) 1.87 ± 0.36 1.87 ± 0.17 1.88 ± 0.17 1.76 ± 0.18 2.11 ± 0.22
Glucose (mmol/L) 12.2 ± 0.90 11.61 ± 0.77 12.5 ± 1.53 12.1 ± 1.17 13.8 ± 2.14
Creatinine (μmol/L) 22.1 ± 3.87 21.0 ± 2.72 20.4 ± 3.79 23.5 ± 5.93 27.9 ± 5.57*
* indicates significant change compared to control groups.
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ring-opened formamidopyrimidine lesions.
Gene expression by RT-PCR
The mRNA was extracted from tissue samples using the
TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Frozen tissue
from each sample was added to TRIzol and homogenized. The
samples were incubated at room temperature for 5 min before
adding 0.2 ml chloroform and centrifuging at 12.000 g for
15 min. The supernatant was transferred to a new tube and the
mRNA precipitated with 0.5 ml isopropanol. The samples were
incubated at room temperature for 10 min before centrifuging at
12.000 g for 10 min. The pellet was washed in ice-cold
75% ethanol followed by centrifugation at 7.600 for 5 min.
The pellet was allowed to air dry. The pellet was resuspended in
30 μl RNase free water by incubation at 55 °C for 10 min.
The extracted mRNA samples were DNase treated using RQ1
RNase-Free DNase kit (Promega, Madison, WI, USA).
The total mRNA was converted into cDNA by reverse
transcriptase PCR using the High Capacity cDNA Transcription
Kit (Applied Biosystems, Carlsbad, CA, USA). A negative
control with no Reverse Transcriptase was included in each run.
The quantification of gene expression was determined by
real-time PCR using the Taqman® gene expression assay. The
probe and primers used were: CCL2 (Rn00580555_m1), CXCL2
(Rn00586403_m1), IL6 (Rn01410330_m1), OGG1
(Rn00578409_m1), HMOX1 (Rn00561387_m1) and as endogenous
control: eukaryotic 18S rRNA (X03205.1), (Applied Biosystems).
All samples were determined as triplicates. The level of mRNAexpression normalized to the level of 18S rRNA was calculated as
2-ΔCt. The relative mRNA levels in the exposure groups were
standardized in order to obtain fold increases in mRNA level
relative to the level in the control groups.
Cytokine levels in plasma
IL6 and TNF-alpha were determined by ELISA (R&D
Systems,MN, USA), according to the manufacturer’s instructions.
Statistics
The statistical analysis for the single dose study was carried
out as a one-factor ANOVA on stratified datasets on micelles or
liposomes. The control group consisted of 8 animals (a pool of the
control animals sacrificed after 24 and 48 h respectively). The
same control group was used for both datasets (micelles
and liposomes). For the dataset on repeated exposures we
used one-factor ANOVA with exposure (control, micelles or
liposomes) as categorical variables. Homogeneity of variance
between groups was assessed by Levene’s test at 5% level. Log-
transformation was necessary for some variables to achieve
homogeneity of variance. The results on HMOX1 in the liver in
the repeated exposure study did not have homogeneity of
variance between groups and these results were thus analysed
by non-parametric Kruskal-Wallis test. Statistically significant
results were accepted when P b 0.05 in the overall ANOVA. The
P-values in the text correspond to the post-hoc least significant
difference tests. The statistical analysis was carried out in
Statistica 5.5 from StatSoft, Inc. (Tulsa, OK, USA). All data are
Table 3
Clinical chemistry and hematology from single dose study for all groups reported as mean ± SD (n = 8) for animals exposed to control (PBS) or liposomes.
Parameters Liposome groups ± SD
Control 10 mg/kg 25 mg/kg 100 mg/kg 100 mg/kg (48 h)
Body weight (g) 141 ± 18.9 133 ± 14.9 133 ± 19.3 133 ± 18.7 144 ± 8.44
Erythrocytes (1012/L) 5.72 ± 5.31 5.65 ± 2.30 6.00 ± 3.12 5.88 ± 2.59 6.15 ± 4.52
Hemoglobin (mmol/L) 7.00 ± 0.42 6.84 ± 0.35 7.04 ± 0.15 7.06 ± 0.31 7.30 ± 0.59
Hematocrit (L/L) 0.35 ± 0.03 0.34 ± 0.01 0.36 ± 0.02 0.36 ± 0.02 0.37 ± 0.04
Thrombocytes (1011/L) 9.12 ± 5.73 9.01 ± 1.31 8.53 ± 1.71 7.20 ± 1.74 6.91 ± 1.68
Leucocytes (109/L) 4.25 ± 1.07 4.16 ± 2.10 4.01 ± 1.49 3.60 ± 7.69 4.48 ± 1.96
Reticulocytes (1011/L) 4.71 ± 6.81 4.79 ± 7.40 4.89 ± 8.17 4.99 ± 8.70 3.69 ± 3.75
Chloride (mmol/L) 99.9 ± 1.25 99.5 ± 1.60 99.6 ± 2.70 98.4 ± 1.92 98.1 ± 3.48
Potassium (mmol/L) 4.41 ± 0.28 4.18 ± 0.33 4.20 ± 0.51 4.29 ± 0.46 4.58 ± 0.85
Sodium (mmol/L) 133 ± 1.73 132 ± 2.39 132 ± 1.53 131 ± 1.19 131 ± 3.58
Bilirubin (μmol/L) 1.04 ± 0.54 0.89 ± 0.43 1.13 ± 0.34 1.41 ± 0.23 0.99 ± 0.36
Alkaline phosphatase (μkat/L) 4.90 ± 0.81 4.76 ± 1.27 5.57 ± 1.21 5.68 ± 1.16 5.06 ± 1.07
Phosphorus (mmol/L) 2.31 ± 0.55 2.25 ± 0.43 2.34 ± 0.44 2.68 ± 0.02 2.35 ± 0.40
Albumin (g/L) 26.7 ± 0.70 26.9 ± 1.23 27.7 ± 1.13 25.1 ± 1.00* 24.6 ± 0.88*
Triglycerides (mmol/L) 1.24 ± 0.30 1.18 ± 0.31 0.85 ± 0.29 0.64 ± 0.28* 1.12 ± 0.37
Aspartat aminotransferase (μkat/L) 1.59 ± 0.28 1.45 ± 0.07 1.58 ± 0.29 1.70 ± 0.24 1.56 ± 0.32
Urea (mmol/L) 7.43 ± 1.20 5.57 ± 1.11* 6.16 ± 1.65 5.47 ± 0.86* 7.12 ± 1.09
Calcium (mmol/L) 3.26 ± 0.22 2.89 ± 0.13* 2.94 ± 0.14 2.96 ± 0.19* 2.98 ± 0.22*
Alanin aminotransferase (μkat/L) 0.88 ± 0.12 0.85 ± 0.09 0.89 ± 0.12 0.93 ± 0.16 0.79 ± 0.12
Cholesterol (mmol/L) 1.87 ± 0.36 1.74 ± 0.15 1.97 ± 0.25 1.86 ± 0.29 2.01 ± 0.47
Glucose (mmol/L) 12.2 ± 0.90 12.1 ± 1.57 11.7 ± 0.75 12.3 ± 1.10 13.2 ± 1.96
Creatinine (μmol/L) 22.1 ± 3.87 20.6 ± 3.91 21.7 ± 2.84 29.0 ± 4.29* 25.6 ± 3.93
* indicates significant change compared to control groups.
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the figures and standard deviation (SD) in the tables.Results
The study was conducted in two setups, where the first study
was a seven day repeated dose toxicity study, with the aim to
observe potential toxicological effects. The results from the first
study were subsequently used for an in-depth investigation of the
response in a single dose exposure setup with three dose levels
and two time points.
Histopathology, bodyweight and clinical signs
There was no effect on BW in animals given cationic particles
as compared to controls (data not shown). No clinical signs of
reactions to treatment and no macroscopic changes were noted.
Furthermore, there were no significant differences in absolute or
relative organ weights between the treated and control groups;
neither did the histopathological examination reveal any findings
associated with the administration of the cationic particles.
Hematology and clinical chemistry
The repeated dose study revealed no significant changes
in hematology or clinical chemistry parameters as described
elsewhere.32
For the single dose study the hematology parameters were
in general within the normal range and none showed any
statistically significant changes in animals exposed to micelles or
liposomes when compared to the controls. Regarding clinical
chemistry, both exposure to micelles and liposomes resulted in asignificant decrease in the concentration of circulating urea and
calcium – the effect appeared to be stabilized after 48 h. The
level of creatinine was increased significantly for the high dose at
100 mg/kg BW for both micelles and liposomes at 24 h and
48 h, respectively (Tables 2 and 3). The micelles induced a
significant increase in the level of albumin, but had no effect on
triglycerides, whereas the liposomes resulted in a significant
decrease in albumin as well as triglycerides (Tables 2 and 3).
All the statistically significant changes in hematology and clinical
chemistry were small. All other parameters in hematology or
clinical chemistry showed no statistically significant changes.
Genotoxicity and gene expression
Exposure to both micelles and liposomes three times during
one week in the repeated dose study increased levels of SB in
lung tissue (Figure 1, A), but not in the liver (Figure 1, B).
Neither exposure increased the level of FPGss of any sampled
tissues. An increase was observed for expression of the pro-
inflammatory cytokines CCL2 and IL6 as well as for the
oxidative stress response gene HMOX1 and the DNA repair
enzyme OGG1 in the liver (Figure 2). The increase was
statistically significant for the groups exposed to micelles. For
the groups exposed to liposomes the same trend appeared, but
the effect was only significant for CCL2 and IL6. In the lung
tissue, no significant effect on gene expression levels was seen
for any of the exposures (Figure 3).
In the single dose study the highest dose of micelles caused
a significant increase in SB in the lung tissue, which was
further increased after 48 h, whereas the rats administered
liposomes showed a significant increase at 25 and 100 mg/kg
BW after 24 h exposure which was diminished after 48 h
Figure 1. DNA damage observed in the 7 day repeated dose study. Rats were
exposed to either PBS as control vehicle (dark bars), micelles (light grey) or
liposomes (dark grey). Data are represented as strand breaks (SB) or FPG
sensitive sites (FPGss) in lung (A) and liver (B). Data are reported as mean level
of 8 animals + SEM. * indicate that P b 0.05 compared to the control group.
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treatments (Figure 4, B).
In the spleen, an increasing trend was seen for the micelle
exposure on the level of SB, but it was not significant, whereas the
liposomes showed a significant increase for all doses tested (100 mg/
kg BW 24 h; P = 0.065), and the effect was decreased after 48 h,
although the level of SB was still significantly higher than among
controls (Figure 4, C). The DNA damage could only be assessed in
lung and spleen tissue as the liver and brain tissue of control animals
were damaged, possibly as a result of the handling of the samples.
The administration of micelles increased the mRNA expression
level ofCCL2 and IL6 in the lung as well asCXCL2 and IL6 in the
spleen at 24 h after the highest dose, whereas there was no increase
observed in the liver (Table 4).Administration of liposomes caused
increased mRNA levels ofCCL2 in the liver 24 h after the highest
dose, although the expression was decreased at the 2 lower doses.
Liposome administration caused no changes in the expression of
genes in the lung, whereas the mRNA levels of CCL2, HMOX1,
CXCL2 andOGG1were decreased in the spleen 24 h after the low
doses (Table 4).
Cytokine levels were measured in plasma from the single
dose study, but the level of both IL6 and TNFα was below
detection limit of the method used for all samples.
Discussion
This study aimed at investigating the toxicological effect of
cationic lipid-based NP carriers with a standard set of in vivotoxicology tests supplemented with assessment of genotoxicity
and gene expression patterns in potential target organs. Biomarkers
often investigated within particle toxicology were assessed.26,36,37
SB levels were increased in both lung and spleen after
administration of liposomes with less response after micelle
treatment, which however, caused more inflammatory gene
expression in these target organs.
Using the general toxicology parameters investigating clinical
signs, histopathology, hematology and clinical chemistry, we
found low to no effect on any of the groups tested as the values
were all within the normal range and levels. When using the
comet assay to further investigate the genotoxic effects, an
adverse effect of treatment was observed in all groups given the
liposomes and for the highest dose of the micelles, indicating that
the comet assay might be a sensitive method that would be of
interest to include in the test battery when assessing NP carriers.
These results are in agreement with another study showing
that cationic liposomes in vitro showed genotoxic effects even at
non-cytotoxic concentrations, where also an increase in surface
charge was correlated with an increase in genotoxicity.26
We used a non-PEGylated type of liposomes in the present
study. These are recognized relatively fast by reticuloendothelial
cells in the liver or spleen due to binding to proteins such as
immunoglobulins, complement proteins and apolipoproteins.
Moreover, it has been shown that non-PEGylated liposomal
doxorubicin had half-life in plasma of 12.5 and 31.7 h after IV
administration of 6 and 10 mg/kg BW, respectively.38 Thus the
difference in dose alone could influence the distribution of
liposomes to the spleen and other organs, where the cationic
properties of the liposomes, which are not protected by PEG,
could interact with the negatively charged surface of the cell
membranes through electrostatic interaction and absorption to
the cell surface resulting in for instance crossing of the cellular
membrane and potentially causing toxicity to the cell.39-41
Cationic liposomes have also been associated with dose-dependent
toxicity and pulmonary inflammation in mice after i.t. instillation.
Dokka et al found that cationic liposomes induced generation of
reactive oxygen species in lung cells causing inflammation and
toxicity due to the cationic head group and not the liposome
itself.42 The DNA damage observed in the present study could
largely be a result of their cationic surface charge, which enables
the particles to cross the cell membrane, thereby interfering with
the intracellular space, which implies that the properties of the
chosen liposome could be of interest in regard to lowering the
toxicity for future applications. The surface of the NPs can cause
oxidative stress resulting in increased intracellular calcium and
gene activation or the intracellular distribution of NPs may affect
mitochondria thereby generating oxidative stress. These pathways
could both lead to inflammation in which DNA damage could be a
possible consequence.25,43,44 The micelles could have a longer
circulation time due to the PEGylation that could increase the
clearance time by phagocytic cells.16,45
The gene expression of HMOX1 is considered to be marker
of oxidative stress, which we previously have found increased
in lung tissue after exposure to NPs.35 The unaltered levels in
the single dose study of HMOX1 in liver, lung and spleen
tissue indicates that the exposure to liposomes and micelles
was not associated with oxidative stress. This is supported by
Figure 2. mRNA level observed in the 7 day repeated dose study in the liver tissue. Rats exposed to either PBS as control vehicle (dark bars), micelles (light grey)
or liposomes (dark grey). The level of the following genes is reported: CCL2 (A); CXCL2 (B); HMOX1 (C); IL6 (D) and OGG1 (E). Data are reported as mean
level of 8 animals + SEM. * indicate that p b 0.05 compared to the control group.
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We have previously observed that repeated exposure to diesel
exhaust particles was associated with unaltered levels of
oxidatively damaged DNA and increased expression of OGG1
in lung tissue.46,47 It indicates that the increased levels of SB
by exposure to liposomes and micelles in the present study
represent lesions that could be generated by non-oxidative
reactions to DNA.
The gene expression of the inflammatory cytokine IL6 was
most consistently increased as observed after exposure to
100 mg/kg BW micelles in lung and spleen in the single dose
study, although there also were increased levels of CCL2 in the
lung and CXCL2 in the spleen. In the repeated dose study the
level of IL6 was increased in the liver after exposure to bothliposomes and micelles. Nevertheless, IL6 in plasma was below
the detection levels of the ELISA methods. This could be due to a
too low sensitivity of the assay or that cytokine production in
these organs contributes little to the systemic levels found in
plasma. A study showed that inhalation of negatively charged
lipid NPs was not associated with pulmonary inflammation
in terms of elevated IL6 in mice after inhaled doses of up to
200 μg.48 It indicates that the cationic charge on our particles
could be a key parameter in the induction of an inflammatory
response.
The two studies described here, had different setups, which
also can have different impact on the animals. After repeated
dosing the animal’s tolerance to the effects of NPs could be
developed. The total dose in the seven day repeated dose study
Figure 3. mRNA level observed in the 7 day repeated dose study in the lung tissue. Rats exposed to either PBS as control vehicle (dark bars), micelles (light grey)
or liposomes (dark grey). The level of the following genes is reported: CCL2 (A); CXCL2 (B); HMOX1 (C); IL6 (D) and OGG1 (E). Data are reported as mean
level of 8 animals + SEM. * indicate that p b 0.05 compared to the control group.
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approach was that this study was designed as a sighting study to
establish where effects were seen, and not to measure how
large the effects were. In the single dose study, the experiment
was performed within a realistic range with regards to both the
duration and dose of the exposure.
The doses of NPs in our study can be compared to Doxil,
which is a PEGylated liposomal doxorubicin that is approved for
treatment of e.g. recurrent ovarian cancer. The liposomal vesicle
in Doxil consists of a single lamellar envelope with a mean size
of 80–90 nm. The total lipid content of Doxil is approximately
16 mg/ml and the doxorubicin is around 2 mg/ml, indicating a
8:1 ratio. Doxil is administered by IV injection once a month in a
dose of 50 mg/m2 (Doxil.com), corresponding to 92 mg for an
adult.49 A pharmacokinetic study used a dose range of 10–80 mg/m2
for IV administration,50 which corresponds to between 18.5-147 mgof Doxil. This would mean that patients treated with Doxil will
receive between 148 mg and 1176 mg of the lipid vehicle,
resulting in between 30 mg/L and 235 mg/L of lipids in blood. In
our treatment regime, the rats were given 10, 25 and 100 mg/kg
BW corresponding to (rats BW: ~135 grams) 1.35, 3.38 and
13.5 mg per rat, which equals 135, 337.5 and 1350 mg/L in the
blood. We included two concentrations close to the clinical use as
well as a higher concentration for possible higher dosing situations.
Overall conclusions from this study are that both NP carriers
showed limited toxicological effects at low doses, whereas
higher doses produced some effects that probably were related
to the cationic surface charge.26 Where the standard general
toxicity parameters did not reveal any systemic changes by the
NPs, the genotoxicity and gene expression responses in potential
target organs showed effects. The liposomes appeared to induce
more toxicity than the micelles, since there were increased DNA
Figure 4. DNA damage observed in the single dose study in the lungs (A& B) and the spleen (C&D) represented as strand breaks (SB) (A&C) and FPG sensitive
sites (FPGss) (B & D). Dashed bars are after 48 h. Data are reported as mean level of 8 animals + SEM. * indicate that p b 0.05 compared to the control group.
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only caused genotoxicity after exposure to the highest dose but,
as opposed to that of the liposomes, the effect did not appear to
decline over the time span tested (24–48 h).
For future testing of the toxicity of NPs it could therefore
be important to include multiple end points rather than only
standard parameters. We would suggest including genotoxicity
and gene expression patterns in potential target organs with the
standard general toxicity test battery in order to determine the full
toxic potential of a NP. Furthermore, it would be of interest to
investigate the effect of PEGylation in more detail.
The use of genotoxicity assessment shows that this is a
sensitive screening method that can be used to assess the toxicity
of compounds with low systemic toxicity, which is already
acknowledged, since the comet assay was introduced as a draft
for OECD guideline for testing of chemicals in 2012.Acknowledgements
The excellent assistance of the Animal Facility, Section
of Neurobiology and Section of Pathology & Clinical Pathology
at H. Lundbeck A/S is gratefully acknowledged.Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.nano.2014.08.004.References
1. Nel A, Xia T, Madler L, Li N. Toxic potential of materials at the
nanolevel. Science 2006;311(5761):622-7.
2. Vega-Villa KR, Takemoto JK, Yanez JA, Remsberg CM, Forrest ML,
Davies NM. Clinical toxicities of nanocarrier systems.Adv Drug Deliv Rev
2008;60(8):929-38.
3. Kagan VE, Bayir H, Shvedova AA. Nanomedicine and nanotoxicology:
two sides of the same coin. Nanomedicine 2005;1(4):313-6.
4. Donaldson K. Resolving the nanoparticles paradox. Nanomedicine (Lond)
2006;1(2):229-34.
5. Kaasgaard T, Andresen TL, Jensen SS, Holte RO, Jensen LT, JorgensenK.
Liposomes containing alkylated methotrexate analogues for phospholipase
A(2) mediated tumor targeted drug delivery. Chem Phys Lipids 2009;157
(2):94-103.
6. Schnyder A, Huwyler J. Drug transport to brain with targeted liposomes.
NeuroRx 2005;2(1):99-107.
7. Re F, Gregori M, Masserini M. Nanotechnology for neurodegenerative
disorders. Nanomedicine 2012;8(Suppl 1):S51-8.
8. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D.
Optimizing liposomes for delivery of chemotherapeutic agents to solid
tumors. Pharmacol Rev 1999;51(4):691-743.
9. Bhaskar S, Tian F, Stoeger T, KreylingW, de la Fuente JM, Grazu V, et al.
Multifunctional Nanocarriers for diagnostics, drug delivery and targeted
treatment across blood–brain barrier: perspectives on tracking and
neuroimaging. Part Fibre Toxicol 2010;7:3.
10. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM,
McCullough J. The big picture on nanomedicine: the state of
investigational and approved nanomedicine products. Nanomedicine
2013;9(1):1-14.
11. Thomas M, Klibanov AM. Non-viral gene therapy: polycation-
mediated DNA delivery. Appl Microbiol Biotechnol 2003;62
(1):27-34.
Table 4
Level of mRNA in the single dose study, data are from lung, liver and spleen and reported as mean ± SD.
mRNA 24 h after micelles
Control 10 mg/kg 25 mg/kg 100 mg/kg 100 mg/kg (48 h)
Lung CCL2 1.76 ± 1.07 1.16 ± 0.91 0.48 ± 0.32 2.24 ± 2.01* 1.91 ± 2.16
CXCL2 0.32 ± 0.33 0.18 ± 0.13 0.14 ± 0.09 0.22 ± 0.18 0.56 ± 1.04
IL6 0.10 ± 0.11 0.16 ± 0.15 0.65 ± 1.55 8.39 ± 6.85* 0.17 ± 0.16
HMOX1 10.5 ± 16.7 3.50 ± 2.39 5.48 ± 2.82 8.21 ± 12.7 4.17 ± 4.11
OGG1 4.83 ± 4.62 1.90 ± 0.97 2.35 ± 0.89 6.40 ± 7.16 16.3 ± 37.8
Liver CCL2 0.36 ± 0.32 0.02 ± 0.01 0.10 ± 0.05 0.06 ± 0.05 0.08 ± 0.08
CXCL2 8.88 ± 7.61 2.92 ± 1.72 7.59 ± 5.07 12.0 ± 14.0 7.48 ± 6.48
HMOX1 4.30 ± 1.43 1.46 ± 0.59 2.50 ± 1.28 2.12 ± 1.29 2.33 ± 1.69
OGG1 1.53 ± 0.49 0.33 ± 0.25 0.52 ± 0.38 2.44 ± 2.20 0.79 ± 0.42
Spleen CCL2 1.37 ± 0.85 0.71 ± 0.40 1.23 ± 1.12 3.94 ± 2.73 1.27 ± 1.31
CXCL2 0.02 ± 0.01 0.01 ± 0.01 0.04 ± 0.04 0.16 ± 0.19* 0.02 ± 0.02
IL6 1.29 ± 1.01 0.83 ± 0.46 0.51 ± 0.31 7.88 ± 10.2* 3.75 ± 4.98
HMOX1 116 ± 81.1 84.6 ± 33.9 70.6 ± 39.0 185 ± 128 50.4 ± 35.8
OGG1 12.0 ± 7.08 12.5 ± 13.8 14.8 ± 10.2 38.7 ± 67.6 3.89 ± 1.94
24 h after Liposomes
Control 10 mg/kg 25 mg/kg 100 mg/kg 100 mg/kg (48 h)
Lung CCL2 1.76 ± 1.07 4.21 ± 7.73 1.49 ± 2.04 3.00 ± 3.24 2.60 ± 2.76
CXCL2 0.32 ± 0.33 0.62 ± 1.09 0.21 ± 0.27 0.24 ± 0.26 0.42 ± 0.48
IL6 0.10 ± 0.11 0.05 ± 0.04 0.08 ± 0.08 0.13 ± 0.12 0.12 ± 0.13
HMOX1 10.5 ± 16.7 31.8 ± 69.9 9.64 ± 16.3 7.09 ± 4.60 8.78 ± 6.56
OGG1 4.83 ± 4.62 2.92 ± 2.33 4.38 ± 5.84 3.56 ± 1.84 4.22 ± 3.74
Liver CCL2 0.36 ± 0.32 0.17 ± 0.10 0.16 ± 0.13 0.81 ± 0.36* 0.11 ± 0.08
CXCL2 8.88 ± 7.61 8.54 ± 4.27 9.23 ± 5.99 13.7 ± 5.73 5.44 ± 3.76
HMOX1 4.30 ± 1.43 3.70 ± 1.57 3.24 ± 0.80 5.41 ± 3.16 3.63 ± 1.94
OGG1 1.53 ± 0.49 2.01 ± 1.03 1.93 ± 0.05 2.85 ± 1.63 1.05 ± 0.37
Spleen CCL2 1.37 ± 0.85 0.47 ± 0.27 1.16 ± 0.72 2.71 ± 2.22 1.30 ± 0.75
CXCL2 0.02 ± 0.01 0.01 ± 0.00 0.01 ± 0.01 0.03 ± 0.03 0.02 ± 0.02
IL6 1.29 ± 1.01 0.98 ± 0.93 1.94 ± 1.18 1.54 ± 0.96 2.64 ± 1.73
HMOX1 116 ± 81.1 39.2 ± 23.9 71.2 ± 38.5 82.1 ± 56.2 119 ± 84.1
OGG1 12.0 ± 7.08 3.75 ± 1.88 7.88 ± 6.09 6.42 ± 3.95 4.35 ± 4.47
* indicates significant increase compared to control group.
476 K.B. Knudsen et al / Nanomedicine: Nanotechnology, Biology, and Medicine 11 (2015) 467–47712. Andresen TL, Jensen SS, Jorgensen K. Advanced strategies in liposomal
cancer therapy: problems and prospects of active and tumor specific drug
release. Prog Lipid Res 2005;44(1):68-97.
13. Arias JL, Clares B, Morales ME, Gallardo V, Ruiz MA. Lipid-based drug
delivery systems for cancer treatment. Curr Drug Targets 2011;12
(8):1151-65.
14. Szebeni J, Baranyi L, Savay S, Milosevits J, Bunger R, Laverman P, et al.
Role of complement activation in hypersensitivity reactions to doxil and
hynic PEG liposomes: experimental and clinical studies. J Liposome Res
2002;12(1–2):165-72.
15. van den Hoven JM, Nemes R, Metselaar JM, Nuijen B, Beijnen JH,
Storm G, et al. Complement activation by PEGylated liposomes
containing prednisolone. Eur J Pharm Sci 2013;49(2):265-71.
16. Moghimi SM, Hunter AC,Murray JC. Long-circulating and target-specific
nanoparticles: theory to practice. Pharmacol Rev 2001;53(2):283-318.
17. Garcia-Garcia E, Andrieux K, Gil S, Couvreur P. Colloidal carriers and
blood–brain barrier (BBB) translocation: a way to deliver drugs to the
brain? Int J Pharm 2005;298(2):274-92.
18. Dai Z, Gjetting T, Mattebjerg MA, Wu C, Andresen TL. Elucidating the
interplay between DNA-condensing and free polycations in gene
transfection through a mechanistic study of linear and branched PEI.
Biomaterials 2011;32(33):8626-34.
19. Hu X, Hu J, Tian J, Ge Z, Zhang G, Luo K, et al. Polyprodrug
amphiphiles: hierarchical assemblies for shape-regulated cellular
internalization, trafficking, and drug delivery. J Am Chem Soc
2013;135(46):17617-29.20. Pereverzeva E, Treschalin I, Bodyagin D, Maksimenko O, Kreuter J,
Gelperina S. Intravenous tolerance of a nanoparticle-based formulation
of doxorubicin in healthy rats. Toxicol Lett 2008;178(1):9-19.
21. Sayes CM, Reed KL, Warheit DB. Assessing toxicity of fine and
nanoparticles: comparing in vitro measurements to in vivo pulmonary
toxicity profiles. Toxicol Sci 2007;97(1):163-80.
22. Moller P, Danielsen PH, Jantzen K, Roursgaard M, Loft S. Oxidatively
damaged DNA in animals exposed to particles. Crit Rev Toxicol 2013;43
(2):96-118.
23. Nel AE, Madler L, Velegol D, Xia T, Hoek EM, Somasundaran P, et al.
Understanding biophysicochemical interactions at the nano-bio inter-
face. Nat Mater 2009;8(7):543-57.
24. Larsen ST, Roursgaard M, Jensen KA, Nielsen GD. Nano titanium
dioxide particles promote allergic sensitization and lung inflammation in
mice. Basic Clin Pharmacol Toxicol 2010;106(2):114-7.
25. Pfaller T, Colognato R, Nelissen I, Favilli F, Casals E, Ooms D, et al.
The suitability of different cellular in vitro immunotoxicity and
genotoxicity methods for the analysis of nanoparticle-induced events.
Nanotoxicology 2010;4(1):52-72.
26. Shah V, Taratula O, Garbuzenko OB, Patil ML, Savla R, Zhang M, et al.
Genotoxicity of different nanocarriers: possible modifications for the
delivery of nucleic acids. Curr Drug Discov Technol 2013;10(1):8-15.
27. Gjetting T, Andresen TL, Christensen CL, Cramer F, Poulsen TT, Poulsen
HS.A simple protocol for preparationof a liposomal vesiclewith encapsulated
plasmid DNA that mediate high accumulation and reporter gene activity in
tumor tissue. Results in Pharma Sciences, 1(1); 2011. p. 49-56.
477K.B. Knudsen et al / Nanomedicine: Nanotechnology, Biology, and Medicine 11 (2015) 467–47728. Forchhammer L, Moller P, Riddervold IS, Bonlokke J, Massling A,
Sigsgaard T, et al. Controlled humanwood smoke exposure: oxidative stress,
inflammation and microvascular function. Part Fibre Toxicol 2012;9:7.
29. Danielsen PH, Loft S, Jacobsen NR, Jensen KA, Autrup H, Ravanat JL,
et al. Oxidative stress, inflammation, and DNA damage in rats after
intratracheal instillation or oral exposure to ambient air and wood smoke
particulate matter. Toxicol Sci 2010;118(2):574-85.
30. Forchhammer L, Johansson C, Loft S,Moller L, Godschalk RW, Langie SA,
et al.Variation in themeasurement ofDNAdamage by comet assaymeasured
by the ECVAG inter-laboratory validation trial. Mutagenesis 2010;25
(2):113-23.
31. Gjetting T, Arildsen NS, Christensen CL, Poulsen TT, Roth JA, Handlos
VN, et al. In vitro and in vivo effects of polyethylene glycol (PEG)-
modified lipid in DOTAP/cholesterol-mediated gene transfection. Int J
Nanomedicine 2010;5:371-83.
32. KnudsenKB, NorthevedH, Ek PK, PerminA, Andresen TL, Larsen S, et al.
Differential toxicological response to positively and negatively charged
nanoparticles in the rat brain. Nanotoxicology 2014;8(7):764-74.
33. Kumar EK, Almdal K, Andresen TL. Synthesis and characterization of
ratiometric nanosensors for pH quantification: a mixed micelle approach.
Chem Commun (Camb) 2012;48(39):4776-8.
34. Knudsen KB, Northeved H, Gjetting T, Permin A, Andresen TL,
Wegener KM, et al. Biodistribution of rhodamine B fluorescence-labeled
cationic nanoparticles in rats. J Nanopart Res 2014, http://dx.doi.org/
10.1007/s11051-013-2221-1(16:2221).
35. Cao Y, Jacobsen NR, Danielsen PH, Lenz AG, Stoeger T, Loft S, et al.
Vascular effects of multi-walled carbon nanotubes in dyslipidemic ApoE−/−
mice and cultured endothelial cells. Toxicol Sci 2014;138(1):104-16.
36. Donaldson K, Poland CA, Schins RP. Possible genotoxic mechanisms of
nanoparticles: criteria for improved test strategies. Nanotoxicology
2010;4:414-20.
37. Borm PJ, Robbins D, Haubold S, Kuhlbusch T, Fissan H, Donaldson K,
et al. The potential risks of nanomaterials: a review carried out for
ECETOC. Part Fibre Toxicol 2006;3:11.
38. Hong RL, Huang CJ, Tseng YL, Pang VF, Chen ST, Liu JJ, et al.
Direct comparison of liposomal doxorubicin with or without
polyethylene glycol coating in C-26 tumor-bearing mice: is surface
coating with polyethylene glycol beneficial? Clin Cancer Res 1999;5
(11):3645-52.39. NakanishiT,Kunisawa J,HayashiA,TsutsumiY,KuboK,NakagawaS, et al.
Positively charged liposome functions as an efficient immunoadjuvant in
inducing cell-mediated immune response to soluble proteins. J Control
Release 1999;61(1–2):233-40.
40. Nakanishi T, Kunisawa J, Hayashi A, Tsutsumi Y, Kubo K,
Nakagawa S, et al. Positively charged liposome functions as an
efficient immunoadjuvant in inducing immune responses to soluble
proteins. Biochem Biophys Res Commun 1997;240(3):793-7.
41. Soenen SJ, Brisson AR, De CM. Addressing the problem of cationic
lipid-mediated toxicity: the magnetoliposome model. Biomaterials
2009;30(22):3691-701.
42. Dokka S, Toledo D, Shi X, Castranova V, Rojanasakul Y. Oxygen
radical-mediated pulmonary toxicity induced by some cationic liposomes.
Pharm Res 2000;17(5):521-5.
43. Oberdorster G, Oberdorster E, Oberdorster J. Nanotoxicology:
an emerging discipline evolving from studies of ultrafine particles.
Environ Health Perspect 2005;113(7):823-39.
44. Schins RP, Knaapen AM. Genotoxicity of poorly soluble particles. Inhal
Toxicol 2007;19(Suppl 1):189-98.
45. Moghimi SM, Szebeni J. Stealth liposomes and long circulating
nanoparticles: critical issues in pharmacokinetics, opsonization and
protein-binding properties. Prog Lipid Res 2003;42(6):463-78.
46. Risom L, Dybdahl M, Moller P, Wallin H, Haug T, Vogel U, et al.
Repeated inhalations of diesel exhaust particles and oxidatively damaged
DNA in young oxoguanine DNA glycosylase (OGG1) deficient mice.
Free Radic Res 2007;41(2):172-81.
47. Risom L, Dybdahl M, Bornholdt J, Vogel U, Wallin H, Moller P, et al.
Oxidative DNA damage and defence gene expression in the mouse lung
after short-term exposure to diesel exhaust particles by inhalation.
Carcinogenesis 2003;24(11):1847-52.
48. NassimiM, Schleh C, Lauenstein HD, Hussein R, HoymannHG, KochW,
et al. A toxicological evaluation of inhaled solid lipid nanoparticles used as
a potential drug delivery system for the lung. Eur J Pharm Biopharm
2010;75(2):107-16.
49. DuBois DDEF. A formula to estimate the approximate surface area if
height and weight be known. Arch Intern Med 1916;17:863-71.
50. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated
liposomal Doxorubicin: review of animal and human studies. Clin
Pharmacokinet 2003;42(5):419-36.
